子類別 專利 [0/4] 期刊論文 [330/333] 圖書 [1/1] 會議論文/會議摘要 [116/180] 鄰近社群 于重元 [19/19] 劉柯俊 [87/107] 劉滄梧 [120/126] 劉界元(2003-2010) [3/3] 夏和雄(1996-2012) [26/31] 夏興國 [51/54] 姜乃榕 [85/97] 常慧如 [40/45] 張俊彥 [234/254] 張光裕 [70/80] 張憶壽 [104/107] 張文祥 [52/54] 張書銘 [89/91] 彭汪嘉康(1996-2007) [120/126] 施能耀 [37/47] 李家惠 [29/29] 李岳倫 [49/55] 林素芳 [32/32] 楊奕馨 [44/45] 江士昇 [90/92] 沈哲宏 [14/16] 洪文俊 [88/92] 莊雙恩 [82/91] 蔡坤志 [32/35] 蔡慧珍 [67/85] 蘇勇曄 [41/41] 蘇振良 [24/25] 郭靜娟 [71/76] 陳尚鴻 [46/49] 陳振陽 [72/72] 陳美霞(2002-2009) [1/1] 陳詩政 [2/2] 陳雅雯 [39/40] 黃智興 [56/57] 黃道揚 [27/27] 丁兆治(2000-2004) [5/5] 其他 [470/478] 劉敏(1996-2007) [60/62] 劉玫英(2004-2006) [2/2] 吳成文(1996-2008) [53/56] 曾思文(1997-2007) [4/4] 李冠德(1997-2004) [4/6] 林景太(1999-2007) [5/5] 楊文光(1996-1999) [21/21] 王全正(1996-2003) [4/4] 莊聲宏(1997-2004) [11/11] 詹宗晃(2000-2008) [2/2] 賴基銘(2004-2008) [41/47] 阮麗蓉(2000-2006) [6/7] 陳俊叡(2003-2007) [6/6] 馬彥英(1997-1999) [1/1] 黃奇英(2005-2007) [9/10] 社群統計 近3年內發表的文件:43(8.30%) 含全文筆數:447(86.29%) 文件下載次數統計 下載大於0次:447(100.00%) 下載大於100次:431(96.42%) 檔案下載總次數:184688(3.25%) 最後更新時間: 2025-02-26 11:56 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 単離抗体,医薬組成物,単離抗体結合体,ダイマー化阻害方法,シグナル伝達... 可標靶ＶＥＧＦＲ２與ＶＥＧＦＲ３的雙功能抗體 Dual-function antibodies targeting ... Dual-function antibodies targeting ... Pan-Asian adapted ESMO clinical pra... Perspectives of the medical oncolog... TCOG T3221 study: The registry of g... Cooperative participation of CagA a... Pan-Asian adapted ESMO clinical pra... Nivolumab plus chemotherapy in pati...

跳至: (選擇年份) 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目51-75 / 518. (共21頁) << < 1 2 3 4 5 6 7 8 9 10 > >> 每頁顯示[10|25|50]項目

日期	題名	關聯
2022-10	Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression	Hepatology. 2022 Oct;76(Suppl.1):S1411-S1412.
2022-09-21	Clustering of chromatin remodeling enzymes predicts prognosis and clinical benefit of therapeutic strategy in pancreatic cancer	International Journal of Medical Sciences. 2022 Sep 21;19(10):1615-1627.
2022-09-15	Predictive value of albumin combined with neutrophil-to-lymphocyte ratio for efficacy and safety profiles in patients with pancreatic ductal adenocarcinoma receiving liposomal irinotecan plus 5-fluorouracil and leucovorin	American Journal of Cancer Research. 2022 Sep 15;12(9):4267-4278.
2022-09	A prospective phase II study of biweekly S-1, leucovorin, and gemcitabine in elderly patients with locally advanced or metastatic pancreatic adenocarcinoma – The Taiwan Cooperative Oncology Group T1217 study	European Journal of Cancer. 2022 Sep;173:123-132.
2022-09	Systemic treatment of advanced unresectable hepatocellular carcinoma after first-line therapy: Expert recommendations from Hong Kong, Singapore, and Taiwan	Liver Cancer. 2022 Sep;11(5):426-439.
2022-09	Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)	Annals of Oncology. 2022 Sep;33(7):S565-S566.
2022-07	Toward collaboration among cancer trials groups in Asia: TCOG perspective	Annals of Oncology. 2022 Jul;33(Suppl. 6):S449.
2022-07	Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: A single institutional experience	Annals of Oncology. 2022 Jul;33(Suppl. 6):S535.
2022-07	Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors	Annals of Oncology. 2022 Jul;33(Suppl. 6):S484.
2022-07	A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer	Annals of Oncology. 2022 Jul;33(Suppl. 6):S478.
2022-06-22	Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: A real-world multicenter study	Frontiers in Oncology. 2022 Jun 22;12:Article number 800842.
2022-06-02	Trial Designs for integrating novel therapeutics into the management of intermediate-stage hepatocellular carcinoma	Journal of Hepatocellular Carcinoma. 2022 Jun 2;9:517-536.
2022-06	Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin	Journal of Hepato-Biliary-Pancreatic Sciences. 2022 Jun;54(5):607-612.
2022-06	Comparative genomic analysis and its prognostic impact on survival between viral hepatitis-related and non-viral hepatitis intrahepatic cholangiocarcinoma	Journal of Clinical Oncology. 2022 Jun;40(16, Suppl.):Abstract number 4120.
2022-06	Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements	Journal of Clinical Oncology. 2022 Jun;40(16, Suppl.):Abstract number 4009.
2022-05-15	Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: A single institution experience	American Journal of Cancer Research. 2022 May 15;12(5):2189-2202.
2022-05	Transcriptional suppression of Dicer by HOXB-AS3/EZH2 complex dictates sorafenib resistance and cancer stemness	Cancer Science. 2022 May;113(5):1601-1612.
2022-04-18	The trinity: Interplay among cancer cells, fibroblasts, and immune cells in pancreatic cancer and implication of CD8(+) T cell-orientated therapy	Biomedicines. 2022 Apr 18;10(4):Article number 926.
2022-04-15	The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan	American Journal of Cancer Research. 2022 Apr 15;12(4):1884-1898.
2022-04-11	Identification of distinct slow mode of reversible adaptation of pancreatic ductal adenocarcinoma to the prolonged acidic pH microenvironment	Journal of Experimental and Clinical Cancer Research. 2022 Apr 11;41:Article number 137.
2022-04	A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study	British Journal of Cancer. 2022 Apr;126(7):1018-1026.
2022-04	Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials	Journal for Immunotherapy of Cancer. 2022 Apr;10(4):Article number e004273.
2022-02-24	Semaphorin 6C suppresses proliferation of pancreatic cancer cells via inhibition of the AKT/GSK3/beta-catenin/cyclin D1 pathway	International Journal of Molecular Sciences. 2022 Feb 24;23(5):Article number 2608.
2022-02-16	Current status of the spectrum and therapeutics of helicobacter pylori-negative mucosa-associated lymphoid tissue lymphoma	Cancers. 2022 Feb 16;14(4):Article number 1005.
2022-02-15	Semaphorin 4C promotes motility and immunosuppressive activity of cancer cells via CRMP3 and PD-L1	American Journal of Cancer Research. 2022 Feb 15;12(2):713-728.

顯示項目51-75 / 518. (共21頁) << < 1 2 3 4 5 6 7 8 9 10 > >> 每頁顯示[10|25|50]項目